Loopbaan van Edward L. Field
Eerdere bekende functies van Edward L. Field
| Bedrijven | Functie | Begin | Einde |
|---|---|---|---|
| BIORESTORATIVE THERAPIES, INC. | Corporate Officer/Principal | 17-02-2015 | 24-07-2017 |
| NUO THERAPEUTICS, INC. | Operationeel Directeur | 08-02-2012 | 30-06-2014 |
Aldagen, Inc.
 Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | Operationeel Directeur | 01-01-2004 | 24-02-2010 |
| Corporate Officer/Principal | 24-02-2010 | 18-10-2010 | |
| President | 01-01-2004 | 24-02-2010 | |
| Inologic, Inc. | President | - | 01-09-2004 |
| Molecumetics Ltd. | President | - | 01-01-2002 |
Opleiding van Edward L. Field
| Duke University | Undergraduate Degree |
| University of Virginia Darden School of Business | Masters Business Admin |
Statistieken
Internationaal
| Verenigde Staten | 8 |
Operationeel
| President | 3 |
| Chief Operating Officer | 2 |
| Corporate Officer/Principal | 2 |
Sectoraal
| Health Technology | 4 |
| Consumer Services | 3 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| NUO THERAPEUTICS, INC. | Health Technology |
| BIORESTORATIVE THERAPIES, INC. | Health Technology |
| Bedrijven in privébezit | 3 |
|---|---|
Aldagen, Inc.
Aldagen, Inc. Pharmaceuticals: GenericHealth Technology Aldagen, Inc. develops and produces pharmaceutical products. It focuses on developing product candidates to address cardiovascular disease. The firm develops ALD-301 for the treatment of critical limb ischemia; ALD-201 for the treatment of ischemic heart failure; and ALD-401 for the post-acute treatment of ischemic stroke. The company also supplies ALDHbr cells for use in investigator-sponsored clinical studies. Aldagen was founded by Andrew E. Balber, Michael Sherman Colvin, Clay Smith and Nelson Chao in March 2000 and is headquartered in Durham, NC. | Health Technology |
| Inologic, Inc. | |
| Molecumetics Ltd. |
- Beurs
- Insiders
- Edward L. Field
- Ervaring
